Gemphire Therapeutics (NASDAQ: GEMP) and Affimed (NASDAQ:AFMD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.

Volatility and Risk

Gemphire Therapeutics has a beta of 3.9, meaning that its stock price is 290% more volatile than the S&P 500. Comparatively, Affimed has a beta of 3.3, meaning that its stock price is 230% more volatile than the S&P 500.


This table compares Gemphire Therapeutics and Affimed’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Gemphire Therapeutics N/A -170.04% -120.55%
Affimed -1,074.37% -72.94% -57.13%

Analyst Recommendations

This is a breakdown of recent ratings for Gemphire Therapeutics and Affimed, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gemphire Therapeutics 0 0 5 0 3.00
Affimed 0 2 1 0 2.33

Gemphire Therapeutics presently has a consensus price target of $25.80, suggesting a potential upside of 169.31%. Affimed has a consensus price target of $6.50, suggesting a potential upside of 246.67%. Given Affimed’s higher probable upside, analysts clearly believe Affimed is more favorable than Gemphire Therapeutics.

Institutional & Insider Ownership

32.2% of Gemphire Therapeutics shares are owned by institutional investors. Comparatively, 40.4% of Affimed shares are owned by institutional investors. 34.0% of Gemphire Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Gemphire Therapeutics and Affimed’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gemphire Therapeutics N/A N/A -$14.58 million ($3.38) -2.83
Affimed $6.88 million 12.17 -$35.65 million ($0.78) -2.40

Gemphire Therapeutics has higher earnings, but lower revenue than Affimed. Gemphire Therapeutics is trading at a lower price-to-earnings ratio than Affimed, indicating that it is currently the more affordable of the two stocks.


Affimed beats Gemphire Therapeutics on 7 of the 13 factors compared between the two stocks.

About Gemphire Therapeutics

Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy. Gemcabene is liver-directed and inhibits apolipoprotein C-III (apoC-III) protein in the liver and may inhibit acetyl-CoA carboxylase (ACC) in the liver. Gemcabene blocks the overall production of hepatic triglycerides and cholesterol. Gemcabene has been tested as monotherapy and in combination with statins and other drugs in over 895 subjects, across approximately 18 Phase I and Phase II clinical trials. Gemcabene is used as an adjunctive therapy to reduce LDL-C, high-sensitivity C-reactive protein (hsCRP) and triglycerides.

About Affimed

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.

Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with's FREE daily email newsletter.